Rienk Pypstra

Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria

Gary J. Noel, Karen Amsler, M. Heep et al. · Antimicrobial Agents and Chemotherapy · 2007 · 190 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

Jennifer Hammond, Robert J. Fountaine, Carla Yunis et al. · New England Journal of Medicine · 2024 · 135 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17

Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

Yehuda Carmeli, José Miguel Cisneros, Mical Paul et al. · The Lancet Infectious Diseases · 2024 · 102 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects

Thomas P. Lodise, Rienk Pypstra, James B. Kahn et al. · Antimicrobial Agents and Chemotherapy · 2007 · 74 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability

H. Lode, Thomas M. File, Lionel A. Mandell et al. · Clinical Therapeutics · 2002 · 67 citations

Pharmacy, Infectious Diseases, Pharmacology +15